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Abstract
Background: MMTV-Wnt1 transgenic mice develop mammary hyperplasia early in development,
followed by the appearance of solitary mammary tumors with a high proportion of cells expressing
early lineage markers and many myoepithelial cells. The occurrence of tumors is accelerated in
experiments that activate FGF proto-oncogenes or remove the tumor suppressor genes Pten or
P53, implying that secondary oncogenic events are required for progression from mammary
hyperplasia to carcinoma. It is not known, however, which oncogenic pathways contribute to
Wnt1-induced tumorigenesis – further experimental manipulation of these mice is needed.
Secondary events also appear to be required for mammary tumorigenesis in MMTV-Neu transgenic
mice because the transgene in the tumors usually contains an acquired mutation that activates the
Neu protein-tyrosine kinase.
Methods: cDNA or DNA from the mammary glands and mammary tumors from MMTV-Wnt1,
MMTV-Wnt1/p53-/-,  MMTV-Neu  transgenic mice, and newly generated MMTV-Wnt1/MMTV-Neu
bitransgenic mice, was sequenced to seek activating mutations in H-Ras, K-Ras, and N-Ras genes, or
in the MMTV-Neu transgene. In addition, tumors from bitransgenic animals were examined to
determine the cellular phenotype.
Results: We found activating mutations at codons 12, 13, and 61 of H-Ras in just over half of the
mammary tumors in MMTV-Wnt1  transgenic mice, and we confirmed the high frequency of
activating mutations of Neu in tumors in MMTV-Neu transgenic mice. Tumors appeared earlier in
bitransgenic MMTV-Wnt1/MMTV-Neu mice, but no Ras or MMTV-Neu mutations were found in
these tumors, which were phenotypically similar to those arising in MMTV-Wnt1 mice. In addition,
no Ras mutations were found in the mammary tumors that arise in MMTV-Wnt1 transgenic mice
lacking an intact P53 gene.
Conclusions:  Tumorigenic properties of cells undergoing functionally significant secondary
mutations in H-Ras or the MMTV-Neu transgene allow selection of those cells in MMTV-Wnt1 and
MMTV-Neu transgenic mice, respectively. Alternative sources of oncogenic potential, such as a
second transgenic oncogene or deficiency of a tumor suppressor gene, can obviate the selective
power of those secondary mutations. These observations are consistent with the notion that
somatic evolution of mouse mammary tumors is influenced by the specific nature of the inherited
cancer-promoting genotype.
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Background
Several transgenic mouse models have been generated in
efforts to identify or confirm genes that can participate in
breast carcinogenesis and to study the pathogenic process
(for review, see [1]). In general, these models have
revealed that a wide variety of proto-oncogenes can initi-
ate mammary tumorigenesis when expressed under the
control of an appropriate promoter (usually the mouse
mammary tumor virus long terminal repeat (MMTV LTR)
or the whey acidic protein (WAP) transcriptional control
domain). They have also revealed that tumorigenesis is a
stochastic process, resulting in the appearance of solitary
tumors in one or a few of the 10 mammary glands several
months after birth, and that secondary mutational events,
inherited deficiencies in tumor suppressor genes, or a
combination of transgenes can accelerate the onset of
tumor growth. In addition, persistent tumor growth gen-
erally requires the continued expression of the initiating
oncogene, unless certain secondary mutations have
occurred to render the tumor independent of the trans-
genic oncogene [2-4].
Despite these generalizations, the characteristics of mam-
mary tumors arising in transgenic mice differ in a fashion
characteristic of the initiating oncogene. For example, the
expression profiles of tumors reflect the transgenic onco-
gene [5]; moreover, those tumors induced by genes that
activate the Ras signaling pathway (for example, polyoma
middle T antigen, ErbB2/Neu, and H-Ras) are more similar
to each other than to tumors induced by components of
the Wnt signaling pathway (Wnt1, β-catenin, and c-Myc)
with respect both to gene expression patterns ([5], S.
Huang et al., in preparation) and to cellular composition
and histology [6-9]. In tumors induced by components of
the Wnt signaling pathway, a high proportion of cells pro-
duce proteins (Sca-1, Keratin 6) associated with early
stages of mammary development, whereas few such cells
are observed in tumors induced by activators of Ras sign-
aling [9]. In addition, the presence of many tumor cells
with myoepithelial features (for example, expression of
smooth muscle actin) and other observations suggest that
in the Wnt pathway oncogenes transform cells positioned
early in the developmental program for mammary tissue,
whereas oncogenes like ErbB2/Neu that activate Ras pro-
teins, either transform cells that are more advanced devel-
opmentally or drive cells to a more mature epithelial
character during oncogenesis.
Efforts to understand these complex pathogenic events
must take into consideration the secondary oncogenic
events that are presumed to be required to convert one or
a few of the many mammary cells expressing a transgenic
oncogene into a frankly tumorigenic cell. Several findings
offer clues to the nature of such secondary events. For
example, the appearance of mammary tumors in MMTV-
Wnt1  transgenic mice can be accelerated by a second
transgene (MMTV-Fgf3, [10]), by proviral insertion muta-
tions in Fgf genes [11-13], and by inherited deficiencies of
P53 or Pten [14,15]. Similarly, tumors appear earlier in
MMTV-c-Myc/MMTV-v-H-Ras  bitransgenic mice than in
monotransgenic mice [16], and, in c-Myc transgenic mice,
tumors that do not require continued expression of c-Myc
usually contain somatically mutated K-Ras2  or  N-Ras
genes [3]. When tumors occur in animals that inherit a
transgene encoding normal ErbB2/Neu protein, the
tumors usually exhibit a secondary somatic mutation of
ErbB2/Neu  that stimulates the protein-tyrosine kinase
activity of the gene product [17].
In this report, we have attempted to identify additional
somatic events that can promote progression to a tumori-
genic phenotype in MMTV-Wnt1 transgenic mice by seek-
ing acquired mutations in Ras. In addition, we have asked
whether accelerating factors, such as inheritance of a sec-
ond transgenic oncogene, MMTV-Neu, or deficiency in a
tumor suppressor gene, p53, diminishes selection for cells
that have acquired potentially oncogenic mutations. In
the course of these studies, we were also able to determine
that the phenotypic properties of tumors arising in
MMTV-Wnt1/MMTV-Neu  bitransgenic mice resemble
those of tumors induced by Wnt rather than Ras signaling.
Methods
Mice and tissues
MMTV-Wnt1  (FVB/NJ-Tg [Wnt1] 1 Hev/J), MMTV-Neu
(FVB/N-Tg [MMTVNeu] 202 Mul/J), and p53-/-  (129-
Trp53tm1Tyj/J) mice were purchased from Jackson Labs
(Bar Harbor, ME, USA) and maintained or backcrossed for
many generations on the FVB background. All mice were
maintained in a specific pathogen-free facility on a stand-
ard diet.
RNA, DNA, and protein extraction from tumors
Mouse mammary tumors were collected at the time of
necropsy or tumor extraction surgery and snap frozen in
liquid nitrogen. Frozen tumors were ground in liquid
nitrogen and the resulting powder was placed in three
tubes containing appropriate buffers. For RNA extraction,
about 50 mg of tumor powder was dissolved in Trizol
(#15596-018; Invitrogen, Carlsbad, CA, USA), followed
by phenol-chloroform extraction and ethanol precipita-
tion. For DNA extraction, about 50 mg of tumor powder
was digested overnight with 2 mg/ml Proteinase K (#1
373 200; Roche, Indianapolis, IN, USA) in 20 mM Tris,
200 mM NaCl, 5 mM EDTA, 0.2% SDS, pH 8.5 buffer, fol-
lowed by phenol-chloroform extraction and ethanol pre-
cipitation. For protein extraction, about 50 mg of tumor
powder was dissolved in 20 mM Tris, 150 mM NaCl, 1%
Triton X, 2 mM EDTA, 1x protease inhibitor cocktail
(complete tablets, #1 697 498, Roche), 1 mM Na3VO4, 40BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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mM NaF, incubated on ice for up to 30 min and cleared
by centrifugation.
Some DNA samples from MMTV-Wnt1 tumors with wild
type, heterozygous or null p53  allele (generated by L.
Donehower [18]) on a mixed genetic background were a
gift from Larry Donehower (Baylor College of Medicine).
Ras and MMTV-Neu cDNA synthesis
Extracted RNA was copied with gene-specific primers to
make cDNA, which was then amplified with the appropri-
ate primers using the SuperScript™ One-Step RT-PCR Kit
(#10928-034; Invitrogen) according to manufacturer's
instructions. For mouse K-Ras and N-Ras amplification,
primer sequences and cycling conditions were kindly pro-
vided by Lewis Chodosh and Robert Boxer (University of
Pennsylvania School of Medicine). Mouse H-Ras codons
3–99 were amplified either with primers generated based
on the sequences provided by Chodosh and Boxer, or
with an additional reverse primer spanning exons 2 and 3:
HARAS.B2: 5'GATCTGCTCCCTGTACTGATGG3'.
MMTV-Neu transgene cDNA was amplified with primers
AB2913 and AB1310 [17], which amplify the region cor-
responding to nucleotides 1492–2117 of rat Neu cDNA.
Amplification products were purified with QIAquick PCR
Purification Kit (#28106; Qiagen, Valencia, CA, USA)
according to manufacturer's instructions.
H-Ras DNA synthesis
Tumor DNA was extracted as described above, and
extracted DNA was amplified with Taq polymerase
(#N808-0152; Roche) in 1 × PCR Buffer (#N808-0006;
Roche), 2.5 mM dNTPs in the presence of the following
primers: mouse H-Ras  exon 1: HRAS.F1A: 5'-CCTT-
GGCTAAGTGTGCTTC-3', HRAS.B1A: 5'-CCACCTCT-
GGCAGGTAG-3'; mouse H-Ras  exon 2: HRAS.F2A: 5'-
GGATTCTCTGGTCTGAGG3-', HRAS.2B2: 5'-GGATAT-
GAGCCAGCTAGC-3'. Amplification was performed for
30 cycles of 15 sec at 94°C, 30 sec at 60°C and 30 sec at
72°C. Amplification products were purified as above.
Sequencing
All sequencing was carried out by the Memorial Sloan-
Kettering Cancer Center (MSKCC) Sequencing Core Facil-
ity. Every cDNA was sequenced with both forward and
reverse primers used for amplification, and some samples
were also sequenced with the nested reverse primer.
Sequencing peaks were inspected for overall integrity and
legibility. The sample was scored as mutant when hetero-
zygous peaks at positions 12,13, 59, and 61 were at least
the same height as the wild type peaks in at least one
sequencing direction. Sequences were also downloaded
into Vector NTI 5.2.5 (InforMax, Inc., Frederick, MD,
USA) program and aligned on the Baylor College of Med-
icine Search Launcher [19] against the sequences depos-
ited in GenBank (mouse H-Ras: nm008284; mouse K-Ras:
xm110615; mouse N-Ras: nm010937, rat Neu: X03362),
to detect mutations (or lack of thereof) in the transcripts.
Immunoblotting and immunohistochemistry
Proteins were extracted from tumors as described above,
and lysates were diluted 1:1 with 2 × sample buffer
(#LC2676, Invitrogen) with 10% β-mercapthoethanol
(#M-3148, Sigma, St. Louis, MO, USA), boiled, loaded on
Novex SDS/PAGE gels (#EC6075BOX; Invitrogen) and
separated by electrophoresis for 1.5 hrs at 125 V and then
stained with Coomassie Blue to estimate protein concen-
trations. Equal amounts of tumor lysates were then
reloaded on the 10% SDS/PAGE gels and separated by
electrophoresis. Separated proteins were transferred onto
nitrocellulose membranes according to the gel manufac-
turer's instructions. Membranes were incubated for 1 hour
with 5% solution of non-fat dried milk (Carnation,
Nestlé, Solon, OH, USA), followed by 1 hour incubation
with rabbit polyclonal antibodies against phospho-ERK,
1:500 dilution, (#9101S; Cell Signaling, Beverly, MA,
USA), total ERK, 1:500 dilution, (#9102; Cell Signaling)
or mouse monoclonal antibody against γ-tubulin, 1:1,000
dilution, (GTU88; Sigma), followed by appropriate sec-
ondary antibodies conjugated with HRP (donkey-anti-
rabbit, 1:10,000, #111-035-144, Jackson Immunochemi-
cals, West Grove, PA, USA; or rat-anti-mouse kappa light
chain, 1:2,000, #2067 1323, Zymed, San Francisco, CA,
USA).
Tissues were fixed in 10% buffered formalin (#SF100-4,
Fisher, Fair Lawn, NJ, USA) for 16–24 hrs, transferred to
70% ethanol, and shipped to be paraffin-embedded and
sectioned at Histoserv (Germantown, MD, USA). Individ-
ual sections were deparaffinized, rehydrated and boiled in
1 mM EDTA for antigen retrieval. Slides were then treated
with peroxidase, followed by incubation with the appro-
priate blocking serum from the Vectastain kits (anti-rat-
ABC-peroxidase, #PK6104; anti-rabbit-ABC-peroxidase, #
PK6101; MOM, # PK2200, Vector Laboratories, Inc., Bur-
lingame, CA, USA) according to manufacturer's instruc-
tions. Primary antibodies against phospho-ERK (rabbit
polyclonal, #9101S; Cell Signaling), keratin 8 (TROMA,
rat polyclonal, Developmental Studies Hybridoma Bank,
Iowa City, IA, USA), smooth muscle actin (SMA, mouse
monoclonal, #M0851; Dako, Carpinteria, CA, USA), or
mouse keratin 6 (rabbit polyclonal, #PRB-169P; Covance,
Princeton, NJ, USA) were applied for 1 hr, followed by an
incubation with biotin-conjugated appropriate secondary
antibody and signal amplification according to Vectastain
kit manufacturer's instructions (Vector Laboratories, Inc.).
Color was developed with NovaRed™ substrate kit (#SK-BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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4800; Vector Laboratories, Inc.) according to manufac-
turer's instructions.
Results
Activating mutations in H-Ras occur in about half of 
mammary tumors in MMTV-Wnt1 mice
Wnt1-induced mammary tumors contain elevated levels
of c-Myc RNA and protein, as expected from stimulation
of the Wnt signaling pathway [20]. Since an H-Ras trans-
gene can hasten tumorigenesis when combined with a c-
Myc transgene [16] and since K-Ras or N-Ras is frequently
mutated in c-Myc-induced tumors [3], we decided to look
for secondary somatic mutations in mammary tumors
arising in MMTV-Wnt1  transgenic mice by sequencing
cDNA copies of Ras  mRNAs in the tumors. Mutations
were scored only if approximately half of the resulting
amplified DNA had the same mutation, implying growth
selection of an oncogenic cell in which the observed
mutation occurred.
Mutations in the H-Ras gene Figure 1
Mutations in the H-Ras gene. Representative examples of somatic mutations in the H-Ras cDNA from primary mammary 
tumors of the MMTV-Wnt1 mice. Sequence chromatograms of codons 12, 13, and 61 are shown as they appear in the forward 
and reverse sequencing directions. Mutant peaks are indicated by arrows. The nucleotide and amino acid alterations are indi-
cated on the right.
Table 1: Frequency and type of H-Ras mutations in MMTV-Wnt1 tumors
Codon mutated Number (% total)
Activating H-Ras mutations CAA61CTA 10 (22%)
GGA12GAA 5 (11%)
CAA61CGA 4 (9%)
CAA61AAA 2 (4%)
CAA61CAT 1 (2%)
GGC13AGA 1 (2%)
GGC13GTT 1 (2%)
H-Ras WT 22 (48%)
Total 46 (100%)
Primary tumor cDNA was amplified and sequenced with H-Ras-specific primers at least once in each direction as described in Methods. Products 
containing mutant peaks equal to or greater in height than the wild type peaks in at least one sequencing direction were scored as mutation-
positive. Mutations in codons 12,13, 59, and 61 were scored as activating mutations.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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We initially sought activating Ras mutations by sequenc-
ing codons 3–99 of H-Ras, 1–98 of N-Ras, and 1–94 of K-
Ras. All of the sequences contain codons 12, 13, 59, and
61 – sites of the mutations most commonly associated
with oncogenic Ras proteins. We found mutations in
codons 12 and 61 of H-Ras, but not in those of N-Ras or
K-Ras in cDNA from the first 10 tumor samples (Figure 1).
We subsequently focused on the H-Ras cDNA and found
activating mutations in codons 12,13, or 61 in 24 of an
additional 36 primary mammary carcinomas (Table 1).
We then examined 20 tumors without activating muta-
tions in H-Ras for activating point mutations in K-Ras and
N-Ras, but failed to find mutations in these two genes. In
addition, we were unable to detect mutant H-Ras cDNA
made from RNA extracted from hyperplastic mammary
glands from MMTV-Wnt1 transgenic mice (n = 6) or from
virgin or lactating mammary glands from non-transgenic
mice (n = 6), implying that, if H-Ras mutations occurred
before the appearance of primary tumors, an insufficient
number of cells in the glands harbored the mutations to
allow detection, and that selection during tumorigenic
growth would be required.
We made a preliminary effort to define the selectable trait
conferred on mammary cells in MMTV-Wnt1 transgenic
mice by an activating mutation in H-Ras. Tumors in these
mice arise after a latency of similar length, have similar
growth characteristics, and metastasize to the lungs with
similar frequencies regardless of whether they do or do
not contain a mutant H-Ras gene (data not shown).
These findings may simply mean that any requirement for
activation of the Ras pathway in Wnt1-induced tumors
may be satisfied by some other means, such as other onco-
genic mutations; this issue is further addressed in a later
section.
We have also used biochemical methods to look for the
consequences of the H-Ras mutations. For example, the
oncogenic activity of mutant Ras proteins in mouse cells
is dependent on the Raf kinase pathway, which phospho-
rylates and activates the ERK1/p44 and ERK2/p42
mitogen-activated protein kinases (MAPKs) [21]. We have
compared levels of phospho-ERK in Wnt1-induced
tumors with mutant and wild type H-Ras genes by protein
blotting and immunohistochemistry (Figure 2). While
tumors induced by an MMTV-v-H-Ras  transgene con-
tained high levels of phospho-ERK, MMTV-Wnt1  and
MMTV-c-Myc-induced tumors had lower levels, independ-
ent of H-Ras mutation status (Figure 2A). Similarly, there
was no difference in phospho-ERK staining patterns in
tumor sections from any of the MMTV-Wnt1-induced
tumors, although intense staining was observed in
MMTV-v-H-Ras induced tumors (Figure 2B). Thus we do
not know which of the several signaling pathways affected
by Ras may be responsible for growth selection of tumor
cells containing H-Ras mutations.
Mammary tumorigenesis is accelerated in MMTV-Wnt1/
MMTV-Neu bitransgenic mice
Her-2/Neu acts in part through the Ras signaling pathway
[22-24], a feature that may account for the remarkable
similarity between the phenotypes of mammary tumors
found in MMTV-Neu and MMTV-v-H-Ras transgenic mice
[25]. These observations suggest that an inherited Neu
transgene might mimic the effects of somatic mutation of
a Ras gene. If so, tumors might arise earlier in MMTV-
Wnt1/MMTV-Neu bitransgenic mice than in mice carrying
a single transgene, and any cells that acquired H-Ras
mutations would not have a selective growth advantage;
hence H-Ras mutations would not be detected in our tests
of tumor genotypes. In addition, with bitransgenic mice,
we could ask whether a co-existing MMTV-Wnt1 trans-
gene eliminated the selective advantage conferred by an
activating mutation in the coding domain of the MMTV-
Neu transgene, and we could ask whether the phenotype
of tumor cells in resulting tumors resembled the pheno-
type of tumors induced by components of the Wnt path-
way, the Neu/Ras pathway, or both.
Therefore we crossed MMTV-Wnt1 transgenic mice to a
MMTV-Neu transgenic line that carries a cDNA encoding
normal rat ErbB2/Neu protein [26]. In the bitransgenic
MMTV-Wnt1/MMTV-Neu progeny, tumors were detected
significantly earlier than in sibling females harboring only
an MMTV-Neu  transgene or in MMTV-Wnt1  transgenic
mice (Figure 3). Over fifty percent (8/14) of the female
MMTV-Wnt1/MMTV-Neu mice developed tumors by 12
weeks of age, twice as early as a similar cohort of MMTV-
Wnt1 mice (t50 = 25 weeks, n = 44), and almost four times
as early as the MMTV-Neu congenic mice (t50 = 39 weeks,
n = 26), maintained in the same facility.
This acceleration of tumor formation demonstrates that
Wnt1  and  Neu  transgenes can cooperate in oncogenic
transformation of the mouse mammary gland. To deter-
mine whether the presence of an inherited Neu transgene
obviated the selective advantage of secondary somatic
mutations in H-Ras, observed in many of the mammary
tumors induced by a single MMTV-Wnt1 transgene (Table
1), we sequenced DNA amplified from H-Ras  RNA
obtained from 11 tumors arising in the MMTV-Wnt1/
MMTV-Neu bitransgenic animals. None of these samples
showed mutations in the first two exons of H-Ras, sup-
porting the notion that the presence of a Neu transgene
provided most or all of the growth advantage attributed to
Ras mutations in MMTV-Wnt1 or MMTV-c-Myc transgenic
mice (Table 1, [3]).BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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Mammary tumors reported in the MMTV-Neu monotrans-
genic line used here have usually acquired mutations in
the Neu coding domain of the transgene, enhancing the
enzymatic activity of its product; about 70% of these
tumors exhibit point mutations, small deletions, or inser-
tions in the extracellular portion of the receptor in or near
the cysteine-rich domain encoded by nucleotides 1492–
2117 of rat Neu cDNA [17]. However, none of 11 mam-
mary tumors derived from MMTV-Wnt1/MMTV-Neu
bitransgenic mice had evidence of mutations in the rele-
vant portions of the Neu transgene. This result has two
implications: that the presence of an inherited MMTV-
Wnt1 transgene strongly diminishes any selective advan-
tage conferred by secondary somatic mutations in the Neu
transgene, and that expression of a wild-type version of
the  Neu  transgene is sufficient to provide the growth
advantage that is apparently conferred by secondary
somatic mutations of H-Ras  in  MMTV-Wnt1-induced
tumors.
Tumors in the MMTV-Wnt1/MMTV-Neu bitransgenic 
mice are morphologically similar to Wnt1-induced 
tumors, despite expression of the Neu transgene
MMTV-Wnt1-induced tumors contain multiple mammary
cell types, and many cells express early lineage markers,
such as Sca-1 and keratin-6 [9]. In contrast, MMTV-Neu-
induced mammary tumors are composed nearly exclu-
sively of luminal epithelial cells and have a low propor-
tion of Sca-1- and keratin-6-positive cells [9]. Remarkably,
all tumors from bitransgenic mice were similar to the
Wnt1-induced tumors, and not to the Neu-induced ones
(Figure 4A). We detected multiple cell types within these
tumors, including smooth muscle actin-positive myoepi-
thelial cells, keratin-8-positive luminal epithelial cells,
and keratin 6-positive cells (Figure 4B, panels a-c).
Expression of the MMTV-Neu transgene was observed in
the luminal epithelial cells from these tumors by immu-
nohistochemistry (Figure 4B, panel d) and by an RT-PCR
assay with transgene-specific primers (Figure 4C).
Activating H-Ras mutations are not found in Wnt1-
induced tumors arising in p53 null mice
We have previously shown that deficiency of p53 dramat-
ically accelerates the appearance of mammary tumors in
MMTV-Wnt1  transgenic mice [14]. More recently,
Gunther  et al. showed that tumors induced by Wnt1
ERK phosphorylation in MMTV-Wnt1 tumors with and without H-Ras mutations Figure 2
ERK phosphorylation in MMTV-Wnt1 tumors with and without H-Ras mutations. (A) Protein lysates from tumors from a 
MMTV-v-H-Ras mouse (first lane) and MMTV-Wnt1 mice with and without activating H-Ras mutations were subjected to elec-
trophoresis in 10% polyacrylamide gels, transferred to a nitrocellulose membrane and then exposed to antibodies against phos-
pho-ERK, total ERK and γ-tubulin as described in Methods. (B) Primary tumor sections from (a) MMTV-v-H-Ras mouse and (b) 
MMTV-Wnt1 mice without activating H-Ras mutations and (c,d) with activating H-Ras mutations were incubated with antibodies 
against phospho-ERK as described in Methods.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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acquire Wnt1 independence in a p53-deficient back-
ground [2]. We therefore asked whether we could detect
H-Ras  mutations in mammary tumors induced by an
MMTV-Wnt1 transgene in a p53-null background; a fail-
ure to find such mutations would imply either that p53 is
somehow required for such mutations to occur or, more
likely, that an inherited deficiency of p53  conferred a
growth advantage to Wnt1-expressing mammary cells that
would outweigh any selective advantage provided by a
secondary somatic mutation in H-Ras.
To explore this issue, we examined cDNA or DNA from 16
tumors from MMTV-Wnt1  transgenic,  p53-/-  mice and
from 11 tumors from MMTV-Wnt1  transgenic,  p53+/-
mice, with or without loss of heterozygosity (LOH).
Wnt1-induced tumors arising on a p53 heterozygous back-
ground, irrespective of the LOH status, contain H-Ras
mutations at a frequency (5/11) similar to that described
above for Wnt1-induced tumors on a wild type p53 back-
ground. Importantly, however, no H-Ras mutations were
found in any of the sixteen Wnt1-induced tumors on a
p53-/- background (P < 0.05). We conclude that an inher-
ited deficiency of p53 is likely to reduce or eliminate, by
an unknown mechanism, any selective growth advantage
that might otherwise be contributed by secondary somatic
mutations of H-Ras in Wnt1-producing mammary cells.
The finding of H-Ras mutations in the small number of
tumors with loss of p53 heterozygosity implies that Ras
mutation occurs before p53  LOH, since Ras  mutations
appear not to confer a selective advantage in p53 null cells.
However, a larger cohort of tumors undergoing LOH at
the p53 locus will be required to establish the conclusion
more firmly.
Discussion
Most contemporary accounts of oncogenesis assume that
multiple mutations affecting tumor suppressor genes and
proto-oncogenes collaborate to convert a normal cell into
a cancer cell. When these genetic events occur sequentially
by somatic mutations during tumor development, it is
assumed that the functionally significant mutations
confer a selective advantage, such as an augmented rate of
growth, protection from apoptosis, or promotion of fur-
ther mutations, which explains why most if not all cells in
a tumor exhibit multiple acquired mutations, consistent
with repeated clonal selection.
In this report, we have used several features of recent stud-
ies of breast carcinogenesis in genetically manipulated
mice to explore the contributions made to a multi-step
oncogenic process by a variety of inherited and somatic
mutations. We have identified mutations in the H-Ras
proto-oncogene as a significant feature of Wnt1-induced
tumorigenesis (Table 1), and we have shown that an
inherited Neu transgene or an inherited deficiency of the
p53 tumor suppressor gene can provide a selective advan-
tage to Wnt1-expressing mammary cells that overrides the
selective advantage conferred by somatic mutation of H-
Ras. This conclusion is based on our failure to find H-Ras
mutations in any tumors arising in bitransgenic (MMTV-
Wnt1/MMTV-Neu) or p53-deficient (MMTV-Wnt1/p53-/-)
mice (Table 2).
It is not difficult to reconcile the lack of H-Ras mutations
in tumors from bitransgenic mice based on the overlap-
ping signaling pathways in which Neu and Ras participate
[22,23,27,28] and on the evidence for similarities in gene
expression profiles and cell-type composition of mouse
mammary tumors induced by these two genes
[5,9,24,25]. However, the absence of H-Ras mutations in
Wnt1-induced tumors from p53 null mice is surprising,
since it is well known that an activated Ras gene can col-
laborate with p53 deficiency to promote both transforma-
tion of cultured cells [29] and tumor formation in vivo. For
example, a mutant K-Ras gene induces lung adenocarcino-
mas more rapidly in p53-deficient than in p53-wild type
mice [30,31], and K-Ras mutations are often accompanied
by loss of p53 function in human cancers of the colon,
Kaplan-Meiyer plot of tumor incidence in MMTV-Neu and  MMTV-Wnt1/MMTV-Neu siblings and in MMTV-Wnt1 histori- cal controls Figure 3
Kaplan-Meiyer plot of tumor incidence in MMTV-Neu and 
MMTV-Wnt1/MMTV-Neu siblings and in MMTV-Wnt1 histori-
cal controls. MMTV-Neu and MMTV-Wnt1/MMTV-Neu female 
mice generated by crossing MMTV-Wnt1 male and MMTV-
Neu female mice were inspected weekly for mammary 
tumors. The number of MMTV-Wnt1 females generated in 
this cross was too low to include in the analysis (n = 4). The 
rate of appearance of tumors in MMTV-Wnt1 females in a 
previously studied cohort maintained under the same condi-
tions is presented instead.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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pancreas, and other organs [32-34]. However, effects of
inherited mutations on the detection of somatic muta-
tions were previously reported in other mouse models.
For example, mammary tumors from MMTV-TGF-α/
MMTV-Neu and from MMTV-Neu/ p53R172H bitransgenic
mice do not contain somatic mutations in the Neu trans-
gene [35,36].
One curious aspect of our findings is the observation of
Ras mutations affecting only H-Ras and never K- or N-Ras
in  Wnt1-induced mammary tumors. This contrasts
sharply with the report by D'Cruz et al. [3] of mutations
affecting mostly K-Ras and also N-Ras, but never H-Ras, in
mouse mammary tumors induced by an MMTV-c-Myc
transgene. However, three tumors from the small cohort
of the MMTV-c-Myc  mice maintained in our lab were
found to carry mutations in H-Ras, and one had a muta-
tion in K-Ras (KP, unpublished data). We do not have an
explanation for these differences in mutation spectrum
and do not know whether they reflect differences in muta-
tional rates at Ras loci (for example, as a consequence of
environmental exposures), differences in the selective
advantage conferred by different mutant Ras proteins in
cells expressing different oncogenes, or differences in the
genetic backgrounds of the mouse lines used.
In the course of these experiments we have also found that
tumors from MMTV-Wnt1/MMTV-Neu  bitransgenic
Tumors from MMTV-Wnt1/MMTV-Neu mice exhibit morphologic characteristics of Wnt1-induced tumors, despite expression  of the Neu transgene Figure 4
Tumors from MMTV-Wnt1/MMTV-Neu mice exhibit morphologic characteristics of Wnt1-induced tumors, despite expression 
of the Neu transgene. (A) Histological appearance of the tumors from (a) MMTV-Neu, (b) MMTV-Wnt1, and (c, d) MMTV-Wnt1/
MMTV-Neu mice. Note solid morphology and scant stroma in the tumor from the MMTV-Neu mouse, in contrast with 
branched ductular architecture and dense stroma of the tumors from MMTV-Wnt1 and bitransgenic mice. (B) Immunohisto-
chemistry on the consecutive sections of the tumor from a bitransgenic mouse with the following mammary lineage markers: 
(a) anti-smooth muscle actin (SMA), (b) anti-keratin 8 (TROMA), (c) anti-keratin 6, and (d) anti-Her2/Neu marker Ab3, was 
performed as described in Methods. The Her2/Neu marker is expressed in a subpopulation of cells similar to the one positive 
for keratin 8. (C) Detection of Neu RNA in mammary glands and tumors. RT-PCR for the rat Neu on the total RNA samples 
from the MMTV-Neu mouse mammary gland (MG) and tumor (MT), MMTV-Wnt1 mouse mammary tumor (MT), and MMTV-
Wnt1/MMTV-Neu mouse mammary tumor (MT) and gland (MG).
Table 2: Frequency of H-Ras mutations in MMTV-Wnt1/p53+/-, MMTV-Wnt1/p53-/-, and MMTV-Wnt1/MMTV-Neu tumors
MMTV-Wnt1/p53+/- MMTV-Wnt1/p53-/- MMTV-Wnt1/MMTV-Neu
With H-Ras mutations 5 (2 with p53 LOH) 0 0
Without H-Ras mutations 6 (3 with p53 LOH) 16 11
Total 11 (5 with p53 LOH) 16 11
Primary tumor cDNAs (11 MMTV-Wnt1/p53-/- samples) or DNAs (5 MMTV-Wnt1/p53-/- samples and all of the MMTV-Wnt1/p53+/- samples) were 
amplified and sequenced with H-Ras-specific primers at least once in each direction, as described in Methods. Mutations were scored by the same 
criteria described in Table 1.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/24
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animals were remarkably similar to those induced in
MMTV-Wnt1 mice, although they appeared much earlier
than tumors in monotransgenic animals, indicating coop-
erative effect of the two transgenes. The dominant effect of
Wnt1 expression in these tumors closely resembles the
dominant effect of the Myc transgene in tumors from the
MMTV-c-Myc/MMTV-Neu and MMTV-c-Myc/MMTV-v-Ha-
Ras bitransgenic mice [6]. This observation suggests that
the Wnt signaling pathway has a dominant effect over the
Ras  signaling pathway in transformation of mammary
epithelial cells. This might be related to the recently
described effects of Wnts on stem cell maintenance during
normal development [37-40]. Dominance of the Wnt
phenotype in this cross might also be explained by a dif-
ference in time and level of transgene expression in the
mammary tissue.
Conclusions
Selection of somatic oncogenic mutations in mouse mam-
mary tumors depends on the nature of inherited factors:
transgenic oncogenes and loss of function mutations in
tumor suppressor genes.
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